<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249752</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0024</org_study_id>
    <nct_id>NCT04249752</nct_id>
  </id_info>
  <brief_title>Biomarkers in Polyradiculoneuropathies</brief_title>
  <acronym>BIP</acronym>
  <official_title>New Biomarkers in Acute and Chronic Inflammatory Demyelinating Polyradiculoneuropathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHU de la Timone, Marseille, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU Carémeau, Nîmes, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Bordeaux, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH de Perpignan, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH de Narbonne, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH de Béziers France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The nodes of Ranvier contain ion channels that enable the rapid propagation of the nerve&#xD;
      impulse. Cell adhesion molecules and glycolipids play an important role in the formation of&#xD;
      the nodes of Ranvier. Antibodies against glycolipids are detected in half of patients with&#xD;
      Guillain-Barré syndrome, an acute inflammatory neuropathy affecting peripheral nerve. The&#xD;
      investigators found that antibodies target cell adhesion molecules at nodes of Ranvier in 10%&#xD;
      of patients with chronic inflammatory demyelinating neuropathy (CIDP), another disabling&#xD;
      neuromuscular disease affecting peripheral nerves. In the majority of patients with GBS or&#xD;
      CIDP, the mechanisms responsible for the neuromuscular disorders are unknown. Our goals are&#xD;
      to identify novel targets of antibodies in patients, this in order to find novel bio-markers&#xD;
      and to better understand the physiopathology of inflammatory neuropathies. This work will&#xD;
      help patient diagnosis and treatment orientation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Inflammatory demyelinating polyradiculoneuropathies are rare disabling autoimmune&#xD;
      diseases affecting the peripheral nervous system. These neuropathies can be acute, when signs&#xD;
      and symptoms raise in less than 1 month (Guillain-Barré syndrome, GBS), or chronic, when&#xD;
      deteriorations continue over more than 2 months from onset (CIDP). About half of GBS patients&#xD;
      present with IgG1 or IgG3 anti-gangliosides antibodies. Gangliosides are glycolipidic&#xD;
      structures mainly localized at the node and paranode areas. In CIDP patients, IgG4&#xD;
      auto-antibodies directed against nodal (Nfasc-186) or paranodal (Nfasc-155, CNTN1, Caspr-1)&#xD;
      proteins are found in 5 to 10 %. In most GBS and CIDP patients, the antigenic target are&#xD;
      unknown and clinical biomarkers are critically lacking to help diagnosis and treatment&#xD;
      orientation. The aim of the present study is to identify new biomarkers in AIDP and CIDP&#xD;
      patients.&#xD;
&#xD;
      Methods : The investigators conduct a national retrospective and prospective study to&#xD;
      identify new antigenic targets in GBS and CIDP patients. Since 2015, the Institute for&#xD;
      Neurosciences of Montpellier and the University Hospitals of Montpellier collect clinical,&#xD;
      immulogical, electrophysiological, and histological data of GBS and CIDP patients. Each&#xD;
      patient whose serum has already been collected gave written informed consent. GBS and CIDP&#xD;
      are diagnosed according to the current criteria. Anti-gangliosides antibodies (by&#xD;
      immunodot-blot) and anti-Nfasc155, -CNTN1, -Nfasc186, and -Caspr-1 antibodies (by ELISA and&#xD;
      cell-binding assay) are assessed in GBS and CIDP patients, respectively. Among CIDP patients&#xD;
      with monoclonal gammapathy, those presenting with anti-MAG antibodies, increasing VEGF, AL&#xD;
      amyloidosis, and neurolymphomatosis are excluded. Patients' serum are also tested by&#xD;
      immunohistochemical staining on wild-type and GalNacT -/- mouse sciatic nerve fibres.&#xD;
&#xD;
      Clinical and electrophysiological phenotypes are compared between patients with positive and&#xD;
      negative immunostaining. Localization of the staining (i.e. node of Ranvier, paranodal&#xD;
      region, and/or myelin sheath) as the subclass and isotype of the autoantibody are specified.&#xD;
&#xD;
      The search for a new antigenic target is performed in GBS and CIDP patients which are i)&#xD;
      seronegatives for antiganglioside and anti-Nfasc155, -CNTN1, -Nfasc186, and -Caspr-1&#xD;
      antibodies, and presenting with ii) a postive immunostaining on wild-type and GalNacT-/-&#xD;
      mouse sciatic nerve fibres. Then, serums of these selected patients are incubated with&#xD;
      neuronal and glial cells in culture (spinal dorsal ganglia, motoneurons, Schwann cells,&#xD;
      oligodendrocytes and neocortical neurons). In the case of positivity against cell culture, an&#xD;
      immunoprecipitation is performed and the antigen/antibody complex is separated on SDS-PAGE&#xD;
      4-12% gel and electrophoretic bands are analyzed by mass spectrometry.&#xD;
&#xD;
      The aim of this study is to identify new antigenic targets in seronegative GBS and CIDP&#xD;
      patients displaying immunoreactivity. The knowledge of these new targets may improve our&#xD;
      diagnostic tools and could help to develop targeted therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between clinical features and immunoreactivity findings in GBS and CIDP patients</measure>
    <time_frame>24 months</time_frame>
    <description>Correlation between the localization of the staining (i.e. node of Ranvier, paranodal region, and/or myelin sheath) and the axonal or demyelinating nature of the neuropathy (according to GBS and CIDP criteria).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Screening and titration of antibodies against new antigenic targets in GBS and CIDP patients.</measure>
    <time_frame>5 years</time_frame>
    <description>The serums of patients will be considered seropositives when optical density value is ≥ 0.1 in ELISA</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Guillain-Barre Syndrome</condition>
  <condition>CIDP</condition>
  <arm_group>
    <arm_group_label>Group 1 with GBS patients</arm_group_label>
    <description>GBS patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 with CIDP patients</arm_group_label>
    <description>with CIDP patients</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, lymphocyte, and cerebrospinal fluid,&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        GBS and CIDP patients according to the diagnostic criteria defined above.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  GBS or CIDP patients over 18 years old&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  With a positive immunostaining on wild-type and GalNacT-/- mouse sciatic nerve fibres.&#xD;
&#xD;
          -  Subjects must be covered by public health insurance&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - seropositive for anti-ganglioside, anti-MAG, and/or anti-Nfasc155, -CNTN1, -Nfasc186, and&#xD;
        -Caspr-1 antibodies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Taieb, MD</last_name>
    <role>Study Director</role>
    <affiliation>UH MONTPELLIER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume Taieb, MD</last_name>
    <phone>467337822</phone>
    <phone_ext>33</phone_ext>
    <email>g-taieb@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jérôme Devaux, PhD</last_name>
    <email>Jerome.devaux@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Taieb, MD</last_name>
      <email>g-taieb@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jérôme Devaux, PhD</last_name>
      <email>Jerome.devaux@inserm.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic inflammatory demyelinating polyradiculoneuropathy</keyword>
  <keyword>immunostaining</keyword>
  <keyword>autoantibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guillain-Barre Syndrome</mesh_term>
    <mesh_term>Polyradiculoneuropathy</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

